The principal objective of the Biostatistics Core will be to provide project investigators a centralized resource for biostatistics expertise. Statistical issues will be addressed at all levels of investigation: from the design of experiments, to the maintenance of data quality;and from conclusions based on formal hypothesis testing, to important leads discovered by thorough data exploration. In support of this objective, the specific aims of the Core include: 1. Collaborate with project investigators in the formulation of unambiguous hypotheses and hypothesis testing strategies, and in the design of laboratory experiments and clinical trials. 2. Provide support for all projects with: formal hypothesis tests in experimental and clinical data that ensure strong conclusions;exploratory analyses that lead to further experiments, refined hypotheses, or discoveries;frequent collaborative meetings about improving design, sample size, and resource use as evidence is accumulated;statistical modeling and sensitivity analyses of complex data;and visual displays of data that clarify conclusions and uncover leads. 3. Provide data transfer, management, and integration services that ensure high integrity, security and investigator accessibility. 4. Investigate new methodologies to directly address difficult data or design problems. With this approach and since the last renewal, strong and productive collaborative relationships have developed with the P01 investigators. Evidence of this is in the list of 44 P01 publications over 4.5 years with biostatistician co-authors.
The Biostatistics Core will provide critical support for planning and design of experiments and studies, statistical analyses and display of data, and data management and integrity. This support is designed to ensure that studies yield reliable conclusions, resources are efficiently used, and exploratory analyses uncover important leads.
|Freud, Aharon G; Mundy-Bosse, Bethany L; Yu, Jianhua et al. (2017) The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity 47:820-833|
|Duggan, Megan C; Stiff, Andrew R; Bainazar, Maryam et al. (2017) Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma. Proc Natl Acad Sci U S A 114:9629-9634|
|Long, Meixiao; Beckwith, Kyle; Do, Priscilla et al. (2017) Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest 127:3052-3064|
|Victor, Aaron R; Nalin, Ansel P; Dong, Wenjuan et al. (2017) IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF-?B. J Immunol 199:2333-2342|
|Wesolowski, Robert; Duggan, Megan C; Stiff, Andrew et al. (2017) Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunol Immunother 66:1437-1447|
|Markowitz, Joseph; Wang, Jiang; Vangundy, Zach et al. (2017) Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration. Sci Rep 7:15424|
|Campbell, Amanda R; Duggan, Megan C; Suarez-Kelly, Lorena P et al. (2017) MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions. Cancer Immunol Res 5:778-789|
|Suarez-Kelly, Lorena P; Campbell, Amanda R; Rampersaud, Isaac V et al. (2017) Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy. Nanomedicine 13:909-920|
|Dai, Hong-Sheng; Griffin, Nathaniel; Bolyard, Chelsea et al. (2017) The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. Immunity 47:159-170.e10|
|McMichael, Elizabeth L; Jaime-Ramirez, Alena Cristina; Guenterberg, Kristan D et al. (2017) IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. Clin Cancer Res 23:489-502|
Showing the most recent 10 out of 283 publications